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Background
Canakinumab (CAN) is indicated for the treatment of
cryopyrin-associated periodic syndrome (CAPS) in
patients ≥2 years of age [1]. However, patients may
require treatment in infancy where CAN has not yet
been studied. IL-1 inhibition has not affected antibody
production after vaccination in healthy volunteers [2],
but no data in patients receiving standard childhood
vaccines are available.
Objectives
To evaluate the efficacy and safety of CAN, including
post-vaccination antibody production, in children with
CAPS <4 years of age.
Methods
CAN-naïve patients aged 28 days to 4 years with CAPS
received open-label CAN dosed 2-12 mg/kg every 4 or
8 weeks for 56 weeks. Efficacy was evaluated by com-
plete response (clinical response and normal C-reactive
protein [CRP]) and subsequent relapse. Safety was
assessed by adverse event (AE) reporting and vaccina-
tion response evaluated by post-vaccine antibody titers
measured at 28 and 57 days post vaccination. Vaccines
evaluated included DTP; H. Flu; N. Men.; influenza;
Hep B; and Strep. Pneum.
Results
Of 17 patients enrolled, 6 were less than 24 months old
(44 days-5 months). The phenotypic distribution was:
FCAS (n=1), MWS (n=12), and NOMID (n=4). All 17
patients achieved a clinical response and 16 achieved a
complete response. Seven patients required dose escala-
tion to achieve and/or maintain their responses. The
patient who did not achieve a complete response was
a 1 year old with persistently elevated CRP. Of the
16 patients with a complete response, 4 (2 with MWS
and 2 with NOMID) subsequently relapsed, but all
regained complete response; 2 (1 MWS; 1 NOMID)
with and 2 (1 MWS; 1 NOMID) without dose escala-
tion. No CAPS flares were reported with vaccination
and a rise in post-vaccination antibody titers was
observed for all vaccines evaluated. The most common
type of AE reported was an infection, typically involving
the upper respiratory tract. Four patients experienced a
serious AE (SAE), with no SAE occurring more than
once. No patient discontinued due to an AE.
Conclusions
Canakinumab is an effective treatment for patients with
CAPS aged as young as 44 days old. Canakinumab
appears to have no effect on the ability to produce anti-
bodies against standard childhood non-live vaccines.
The safety profile of canakinumab was acceptable and
similar to that observed for older patients.
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